ATOSSA THERAPEUTICS, INC.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
ATOS$2.14+0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders' Equity
(amounts in thousands, except share data)
| Total | ||||||||
|---|---|---|---|---|---|---|---|---|
| Convertible Preferred Stock · Common Stock · Additional · Treasury Stock · Accumulated · Stockholders' | ||||||||
| Shares | Amount | Shares | Amount | Paid-in Capital | Amount | Deficit | Equity | |
| Balance at December 31, 2024 | 582 | $— | 8,611,266 | $1,550 | $283,194 | $(1,475) | $(211,792) | $71,477 |
| Stock-based compensation | — | — | — | — | 563 | — | — | 563 |
| Net loss | — | — | — | — | — | — | (6,718) | (6,718) |
| Balance at March 31, 2025 | 582 | $— | 8,611,266 | $1,550 | $283,757 | $(1,475) | $(218,510) | $65,322 |
| Issuance of common stock upon Series B preferred stock conversion | (5) | — | 95 | — | — | — | — | — |
| Stock-based compensation | — | — | — | — | 796 | — | — | 796 |
| Net loss | — | — | — | — | — | — | (8,423) | (8,423) |
| Balance at June 30, 2025 | 577 | $— | 8,611,361 | $1,550 | $284,553 | $(1,475) | $(226,933) | $57,695 |
| Stock-based compensation | — | — | — | — | 784 | — | — | 784 |
| Net loss | — | — | — | — | — | — | (8,692) | (8,692) |
| Balance at September 30, 2025 | 577 | $— | 8,611,361 | $1,550 | $285,337 | $(1,475) | $(235,625) | $49,787 |
| Total | ||||||||
| Convertible Preferred Stock · Common Stock · Additional · Treasury Stock · Accumulated · Stockholders' | ||||||||
| Shares | Amount | Shares | Amount | Paid-in Capital | Amount | Deficit | Equity | |
| Balance at December 31, 2025 | 577 | $— | 8,611,361 | $1,550 | $285,840 | $(1,475) | $(246,562) | $39,353 |
| Stock-based compensation | — | — | — | — | 722 | — | — | 722 |
| Net loss | — | — | — | — | — | — | (9,589) | (9,589) |
| Balance at March 31, 2026 | 577 | $— | 8,611,361 | $1,550 | $286,562 | $(1,475) | $(256,151) | $30,486 |
| Stock-based compensation | — | — | — | — | 815 | — | — | 815 |
| Issuance of common stock under ATM program, net of issuance costs | — | — | 4,300 | 1 | 20 | — | — | 21 |
| Registered direct offering | — | — | 1,363,637 | 245 | 4,255 | — | — | 4,500 |
| Issuance costs relating to registered direct offering | — | — | — | — | (501) | — | — | (501) |
| Net loss | — | — | — | — | — | — | (8,491) | (8,491) |
| Balance at June 30, 2026 | 577 | $— | 9,979,298 | $1,796 | $291,151 | $(1,475) | $(264,642) | $26,830 |
| Stock-based compensation | — | — | — | — | 547 | — | — | 547 |
| Net loss | — | — | — | — | — | — | (5,638) | (5,638) |
| Balance at September 30, 2026 | 577 | $— | 9,979,298 | $1,796 | $291,698 | $(1,475) | $(270,280) | $21,739 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.